- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Axura® | Ebixa® | Namenda®
memantine is an approved drug (EMA (2002), FDA (2003))
Compound class: Synthetic organic
Comment: Memantine is a non-competitive NMDA receptor antagonist approved for Alzheimer's disease but is also being studied in non-dementia psychiatric disorders  .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: memantine
|No information available.|
|Summary of Clinical Use|
|Memantine reduces clinical worsening in moderate to severe AD .
Memantine is a component of the approved AD fixed-dose medication Namzaric® (which contains memantine plus donepezil).
|Mechanism Of Action and Pharmacodynamic Effects|
|Memantine blocks NMDA glutamate channels. For a complete overview of the mechanism of action of memantine, please see the DrugBank link on the Summary tab of this ligand page..|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)